KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare.
Exit since Feb. 2011. Purchaser: Evotec AG
Dr. Andreas Jenne
Evotec acquires Kinaxo, Profitable Exit for Seed-Investor High-Tech Gründerfonds
Evotec expands its drug discovery platform with cutting-edge technologies Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted…
Am Klopferspitz 19a
21. Jul 2006 – 09. Feb 2011